|| List of recent Expression Vector-related patents
|Production of therapeutic proteins in genetically modified mammalian cells|
The invention relates to methods for the production of therapeutic proteins in mammalian cells. In one embodiment, the method comprises producing a therapeutic protein such as igf-1 in a mammalian cell endogenously expressing a cognate receptor of said recombinant therapeutic protein and wherein binding of said therapeutic protein to said cognate receptor results in a low titer of the therapeutic protein, the method comprising with a mammalian cell being deficient in the expression of the cognate receptor of said therapeutic protein and being transformed with an expression vector comprising a nucleic acid molecule encoding the therapeutic protein: a.
|Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells|
Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (hsc) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increase a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers.
Children's Hospital Medical Center
Isolated polynucleotides comprising a slc6a4 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
|Mitochondrial expression vector and the transformation of mitochondria|
The invention relates to a mitochondrial expression vector which may comprise a gene to be expressed and/or a selection marker and a mitochondrial region, and a method for inserting a dna to be expressed into mitochondria of mammalian cells, wherein the method may comprise the steps: (i) construction of a mitochondrial expression vector or a mitochondrial genome, (ii) reversible induction of megamitochondria and (iii) transfection of the megamitochondria by means of a physical transfection method.. .
|Tobacco specific nitrosamine reduction in plants|
In one aspect, there is provided a mutant, non-naturally occurring or transgenic plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a member of the clc family of chloride channels and having at least 60% sequence identity to seq id no:1 or seq id no:2 or seq id no:3 or seq id no:4 or seq id no:10 or seq id no:11; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence encoding a member of the clc family of chloride channels and having at least 60% sequence identity to seq id no:5 or seq id no:6 or seq id no:7 or seq id no:12 or seq id no:13 or seq id no:14; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i); and wherein the expression or activity of the polynucleotide or the polypeptide is modulated as compared to a control plant and wherein the nitrate levels in the mutant, non-naturally occurring or transgenic plant containing the mutant, non-naturally occurring or transgenic plant cell are modulated as compared to the control plant containing the control plant cell.. .
Philip Morris Products S.a.
|Dual-target antibody targeting vegfr-2 and dll4, and pharmaceutical composition including same|
The present invention relates to a novel form of a dual-target antibody targeting vegfr-2 and dll4, a gene encoding the same, a recombinant expression vector including the gene, host cells transformed with the recombinant expression vector, a method of producing the dual-target antibody using the host cells, a pharmaceutical composition comprising the dual-target antibody.. .
|Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof|
The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i.e., thermal and chemical) stability.
Bristol-myers Squibb Company
|Engineered receptors and their use|
Engineered chloride channel receptors, nucleic acids encoding these receptors, expression vectors including these nucleic acids are disclosed herein. Nanoparticles and pharmaceutical compositions including these engineered chloride channel receptors, nucleic acids, and expression vectors are disclosed.
University Of Pittsburgh-of The Commonwealth System Of Higher Education
|Mutant beta-glucosidases having enhanced activity and a producing bioethanol using the same|
The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant.
Korea Research Institute Of Bioscience And Biotechnology
The invention provides nucleic acids encoding mutants of the acetohydroxyacid synthase (ahas) large subunit comprising at least two mutations, for example double and triple mutants, which are useful for producing transgenic or non-transgenic plants with improved levels of tolerance to ahas-inhibiting herbicides. The invention also provides expression vectors, cells, plants comprising the polynucleotides encoding the ahas large subunit double and triple mutants, plants comprising two or more ahas large subunit single mutant polypeptides, and methods for making and using the same..
Basf Plant Science Gmbh
Biomass production increasing gene and transgenic plant using same
The present invention relates to, inter alia, a gene which increases biomass production isolated from arabidopsis thaliana, and a method for producing a transgenic plant by using same. More specifically, the present invention provides, inter alia, a composition, a recombinant expression vector and a transgenic plant for increasing plant biomass production, comprising a base sequence coding for the amino acid sequence of sequence number 2.
Postech Academy-industry Foundation
Construction of pool of interfering nucleic acids covering entire rna target sequence and related compositions
The present invention provides a pcr based high-throughput method for preparing full-sites sirna polynucleotide pool, comprising: dnase i random digestion; loop-1 phosphate linker ligation; single pcr amplification; a type iii restriction/modification enzyme digestion; blunt ending; loop-2 phosphate linker ligation; double primer pcr; foki digestion and cloning into an sirna expression vector. The present invention enables the use of a type iii restriction/modification enzyme linkers mediated pcr method for high-throughput preparing an sirina polynucleotide pool, in which the functional length of sirnas can be controllably distributed from 19-23 bp, thus completely mimic the natural sirna length diversity, specially suitable for rnai therapeutic targets screening.
Biomics Biotechnologies Co., Ltd.
Egvii endoglucanase and nucleic acids encoding the same
The present invention provides a novel endoglucanase nucleic acid sequence, designated egl7, and the corresponding egvii amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding egvii, recombinant egvii proteins and methods for producing the same..
Danisco Us Inc.
Bi-specific antigen-binding polypeptides
The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to her2 and antagonize her2 activation.
M971 chimeric antigen receptors
The invention provides a chimeric antigen receptor (car) comprising an antigen binding domain comprising seq id nos: 1-6, a transmembrane domain, and an intracellular t cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America,as Represented By The Secretary, Department Of Health And Human Service
Alpha-conotoxin peptide, pharmaceutical composition and use thereof
The present invention provides a novel α-conotoxin peptide, pharmaceutical composition and use thereof. The present invention further provides a propeptide of the conotoxin peptide, a nucleic acid construct, expression vector and transformed cell of the conotoxin peptide as well as a fused protein of the conotoxin peptide.
Methods for treating disorders associated with human signal peptide-containing molecules
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Inhibition of fibrosis and af by tgf-beta inhibition in the posterior left atrium (pla)
The disclosed methods pertain to diagnosing whether a non-ablative, gene therapy is needed for reducing af fibrosis in a subject, and if so, methods of reducing af fibrosis in a subject using gene therapy with a dominant negative tgf-β r2 cdna expression vector. Kits and computer program products are also described, wherein the kits provide materials for diagnosing and treating af fibrosis, and the computer program products include a computer readable medium having computer readable program code for monitoring the efficacy of therapeutic ablation of fibrosis in a subject using a gene therapy method..
Univariant extrinsic initiator control system for microbes and an in vitro assembly of large recombinant dna molecules from multiple components
The invention provides, inter alia, a nucleic acid (e.g. expression vector) that comprises at least a first coding sequence and a second coding sequence.
Chimeric polypeptides having targeted binding specificity
Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.
Bgl7 beta-glucosidase and nucleic acids encoding the same
The present invention provides a novel β-glucosidase nucleic acid sequence, designated bgl7, and the corresponding bgl7 amino acid sequence. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding bgl7, recombinant bgl7 proteins and methods for producing the same..
Method for forming a reversible protein nanocluster using light in a cell
To efficiently analyze interaction and function between proteins, the present invention relates to a method for forming a light-induced protein nanocluster, comprising: an expression vector preparation step of preparing a first expression vector including polynucleotides coding a first fusion protein including a light-induced heterodimer-forming protein and a first self-assembly protein, and a second expression vector including polynucleotides coding a couple protein that forms a homodimer with said light-induced heterodimer-forming protein, or a second fusion protein including said couple protein and a second self-assembly protein; a transformed cell, tissue or individual preparation step of transforming cells, tissues or individuals using said first expression vector and second expression vector; and a light radiation step of radiating light having a wavelength for inducing the formation of heterodimer between said light-induced heterodimer-forming protein and said couple protein, to said transformed cells, tissue or individuals.. .
Method for crystallization of trx-txnip complex mutein and 3d structure thereof
The present invention relates to a modified txnip protein, a method for preparing the modified txnip protein, a polynucleotide encoding the modified protein, an expression vector including the polynucleotide, a transformant introduced with the expression vector, a method for crystallizing a modified trx-txnip complex using the modified txnip protein, and a method for screening a substance regulating interaction between trx and txnip, an inhibitor of trx activity, or a substance regulating txnip function.. .
Novel human genes relating to respiratory diseases and obesity
This invention relates to isolated nucleic acids comprising genes of human chromosome 12q23-qter and the proteins encoded by these genes. Expression vectors and host cells containing such genes or fragments thereof, as well as antibodies to the proteins encoded by these nucleic acids are also included herein..
Oscient Pharmaceuticals Corporation
Novel recombinant bi-functional fusion proteins, preparation and use thereof
A recombinant bi-functional fusion protein, comprising an ig region of an extracellular domain of a signal-regulator protein (sirp), linked via a fc fragment of an ig, to an ig region of an extracellular domain of vegfr, wherein the protein can bind to cd47 and vegf simultaneously, blocking the binding of cd47 with the sirp on the cell surface of macrophages to stimulate the phagocytosis of tumor cells by macrophages, and inhibiting the growth of vascular endothelial cells induced by vegf. The present application also provides a nucleic acid molecule encoding the recombinant bi-functional fusion protein and an expression vector expressing the protein, a method for producing the protein and a method for treating a disease over-expressing cd47 or vegf..
Dpp8 and dpp9 peptide inhibitors
The present invention relates to non-competitive allosteric peptide inhibitors of dpp9 and/or dpp8, competitive peptides binding to sumo1, nucleic acid molecules and expression vectors coding said peptide inhibitors, host cells expressing said inhibitors, kits comprising said inhibitors, as well as methods of producing said inhibitors, and uses of said peptide inhibitors; as further defined in the claims.. .
Georg-august-universitat Gottingen Stiftung Offentlichen Rechts, Universitatsmedizin
Isolated polynucleotides comprising a ugt8 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
Gitr binding molecules and uses therefor
The present invention provides binding molecules that specifically bind to gitr, e.g., human gitr (hgitr), on t cells and dendritic cells. Binding molecules of the invention are characterized by binding to hgitr with high affinity, in the presence of a stimulating agent, e.g., cd3, are agonistic, and abrogate the suppression of teff cells by treg cells.
Compositions and methods for enhanced gene expression in cone cells
The present disclosure provides polynucleotide cassettes, expression vectors and methods for the expression of a gene in cone cells.. .
University Of Washington
Intrathecal delivery of recombinant adeno-associated virus 9
The present invention relates to adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as sma and als as well as pompe disease and lysosomal storage disorders.
Ohio State Innovation Foundation
Expression vectors comprising the mcmv ie2 promoter
The invention relates to an expression vector comprising the promoter of the mcmv-ie2 gene, or a functional expression promoting fragment thereof, and/or an enhancer of the mcmv-ie2 gene, or a functional expression enhancing fragment thereof, wherein the expression vector does not contain any complete gene of the mcmv.. .
Merck Serono S.a.
Fungal resistant plants expressing hcp4
The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an hcp4 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh
Methods and compositions comprising human recombinant growth and differentiation factor-5 (rhgdf-5)
expression vector systems are provided for increased production of a recombinant gdf-5 (rhgdf-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhgdf-5 protein.
Warsaw Orthopdedic, Inc.
Regenerating functional neurons for treatment of disease and injury in the nervous system
Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing neurod1 into a glial cell, particularly into a reactive astrocyte or ng2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous neurod1 in the glial cell, wherein expressing exogenous neurod1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous neurod1 to the glial cell..
The Penn State Research Foundation
Photosynthetic resource use efficiency in plants expressing regulatory proteins
Polynucleotides and polypeptides incorporated into expression vectors are introduced into plants and were ectopically expressed. These polypeptides may confer at least one regulatory activity and increased photosynthetic resource use efficiency, increased yield, greater vigor, greater biomass as compared to a control plant..
Koch Biological Solutions, Llc
T cell receptors recognizing mhc class ii-restricted mage-a3
The invention provides an isolated or purified t-cell receptor (tcr) having antigenic specificity for mhc class ii-restricted mage-a3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services
Isolated polynucleotides comprising a pcp2 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
Transformant of schizosaccharomyces pombe mutant and cloning vector
Provided is a transformant of s. Pombe mutant which can produce and collect β-glucosidase without requiring complicated separation steps, and a vector which is useful for transforming a yeast of the genus schizosaccharomyces.
Asahi Glass Company, Limited
Novel monoclonal antibody which is specifically bound to tm4sf5 protein and use thereof
The present invention relates to a novel monoclonal antibody which is specifically bound to a transmembrane 4 l six family member 5 (tm4sf5) protein. More particularly, the present invention relates to a monoclonal antibody which is specifically bound to a human tm4sf5 protein, to polynucleotides coding for the monoclonal antibody, to an expression vector comprising the nucleotides, to a transformant with the vector introduced thereto, to a method for preparing the monoclonal antibody, to a composition comprising the monoclonal antibody, to a method for treating liver fibrosis using the monoclonal antibody, to a method for treating cancer using the monoclonal antibody, to a method for inhibiting metastasis of cancer, to a method for diagnosing cancer using the monoclonal antibody and to a cancer diagnosis kit comprising the monoclonal antibody..
Snu R&db Foundation
Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
Antibodies and antigen-binding molecules directed against hepatitis c virus (hcv) are presented. The antibodies and antigen-binding molecules specifically bind to the hcv e1e2 complex.
Universite Joseph Fourier (grenoble)
Compositions and methods for increasing the expression and signalling of proteins on cell surfaces
The present invention relates to the field of protein expression. More specifically, the present invention provides compositions and methods for increasing the expression and signaling of proteins on cell surfaces.
Johns Hopkins University
Heavy metal reduction in planta
There is described a mutant, non-naturally occurring or transgenic plant or plant cell comprising (a) a polynucleotide selected from the group consisting of: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 71% sequence identity to seq id nos: 1, 2, 27, 28 or 29 or 51; or (ii) a polynucleotide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos: 3 to 23 or 30 to 50; or (iii) a polynucleotide encoding a ntmrp polypeptide comprising, consisting or consisting essentially of a sequence having at least 65% sequence identity to any of seq id nos. 24 to 26 or 52, and wherein the polypeptide has heavy metal transporter activity; or (b) a polynucleotide construct of at least 15 contiguous nucleotides in length that is at least 65% identical to a region of any of seq id nos: 1 to 23 or 27 to 51; or (c) a double-stranded rna comprising at least two sequences that are at least partially complementary to each other and wherein a sense strand comprises a first sequence and an antisense strand comprises a second sequence and wherein at least one of the sequences comprises at least 10 contiguous nucleotides of ntmrp rna; or (d) an expression vector comprising the polynucleotide as set forth in (i), (ii) or (iii) or the polynucleotide construct as set forth in (b)..
Philip Morris Products S.a.
Dna polymerases having improved labeled nucleotide incorporation properties
In addition to providing novel mutant dna polymerases, the invention also provides polynucleotides encoding the subject mutant dna polymerases. The polynucleotides provided may comprise expression vectors for the recombinant production of the mutant polymerases.
Brown adipocyte differentiation-inducing agent
The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) creg1 protein or (2) an expression vector carrying creg1 gene..
Chubu University Educational Foundation
Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
The present invention relates to use of cometin in a method of treatment of allodynia, hyperalgesia, spontaneous pain and/or phantom pain. In a preferred embodiment the disorder to be treated is thermal allodynia and thermal hyperalgesia.
Methods for sustained and regulatable gene expression using viral based expression vectors
Disclosed are genetic expression cassettes, and vectors comprising them useful for the delivery of isolated nucleic acid segments including those expressing or encoding one or more selected therapeutic constructs (including, without limitation, therapeutic peptides, polypeptides, ribozymes, or catalytic rna molecules), to one or more selected cells or tissues of a vertebrate animal. Methods employing the disclosed genetic constructs in the development of gene therapy-based viral vector systems are also disclosed.
University Of Florida Research Foundation, Inc.
Importation of mitochodrial protein by an enhanced allotopic approach
An expression vector containing appropriate mitochondrion-targeting sequences (mts) and appropriate 3′utr sequences provides efficient and stable delivery of a mrna encoding a protein (cds) to the mitochondrion of a mammalian cell. The mts and 3′utr sequences guide the cds mrna from the nuclear compartment of the cell to mitochondrion-bound polysomes, where the cds is translated.
Institut National De La Sante Et De La Recherche Medicale (inserm)
Expression vectors comprising ires element and the multiple expression gene system thereof
The present invention provides an expression vector comprising an internal ribosome entry site (ires) element, comprising a sequence of seq id no: 1, wherein the sequence is an ires element from a gene icp35 of white spot syndrome virus. The expression vector can be easily operated in insect cells or crustacean cells and has excellent expression efficiency due to having such an ires element.
National Taiwan University
Protein production method
This invention relates to a method for producing a protein of interest, comprising introducing a protein expression vector which comprises a gene fragment a gene fragment comprising a dna encoding a protein of interest and a selectable marker gene and transposon sequences at both terminals of the gene fragment, into a suspension mammalian cell; integrating the gene fragment inserted between a pair of the transposon sequences, into a chromosome of the mammalian cell to obtain a mammalian cell capable of expressing the protein of interest; and suspension-culturing the mammalian cell; and a suspension mammalian cell capable of expressing the protein of interest.. .
Inter-university Research-institute Corporation Research Organization Of Information & Systems
Cytochrome p450 and use thereof for the enzymatic oxidation of terpenes
The present invention provides the nucleic acid and the amino acid sequences of a cytochrome p450 capable of oxidizing terpene molecules. It also provides a method of oxidizing terpene molecules comprising contacting the cytochrome p450 of the invention with the terpene molecule intended to be oxidized.
Expression vectors comprising chimeric cytomegalovirus promoter and enhancer sequences
The present invention relates to expression vectors for the heterologous expression of a nucleic acid sequence of interest in mammalian cells, the vectors comprising a chimeric promoter regulatory sequence being operably linked to a nucleic acid sequence to be expressed, wherein the chimeric promoter regulatory sequence comprises a cytomegalovirus promoter sequence derived from murine cytomegalovirus or from human cytomegalovirus and being operably linked to the transcriptional start site of the nucleic acid sequence to be expressed; and a cytomegalovirus upstream region and/or enhancer sequence derived from human and/or the simian cytomegalovirus, wherein the upstream region and/or enhancer sequence is located 5′ of and operably linked to the murine or the human promoter sequence, and wherein the chimeric promoter regulatory sequence comprises sequence elements being derived from at least two of the group consisting of murine cytomegalovirus, human cytomegalovirus and simian cytomegalovirus. In particular embodiments, the chimeric promoter regulatory sequence comprises sequence elements derived from the murine or the human cytomegalovirus ie1 promoter and from the human and/or the simian cytomegalovirus ie1 region.
Lonza Biologics Plc.
Fungal resistant plants expressing rlk1
The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an rlk1 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh
Synthetic promoter for modulating gene expression
The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed using selected pdx-1 activation sites such as those observed in the human insulin promoter (hip). In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide..
Baylor College Of Medicine
Rnai based selection system
The present invention provides a novel rnai based selection system for selecting host cells that have incorporated an expression vector.. .
Fcrn antagonists and methods of use
Provided are novel fcrn antagonist compositions comprising a variant fc region that binds specifically to fcrn with increased affinity and reduced ph dependence relative to the native fc region. Also provided are fcrn antagonists with enhanced cd16 binding affinity.
The Board Of Regents Of The University Of Texas System
Compositions and methods for treating cardiovascular diseases using smad3
The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter linked to a gene encoding a therapeutic agent, such as a protein, microrna, sirna or other therapeutical molecule, e.g., other oligonucletide. A variety of different promoters may be used with the present invention, provided that any disease specific promoter preferentially expresses the gene linked to it at the site of the disease and not more globally within the body.
Cellular vaccine and inducing an immune response in a subject
The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd
Cytochrome p450 suicide gene system
The invention relates to a modified human cyp4b1 protein and a nucleic acid encoding for the modified human cyp4b1 protein. The invention further relates to an expression vector comprising a nucleic acid encoding for a modified human cyp4b1 protein, as well as to a cell comprising a modified cyp4b1 protein.
Fungal resistant plants expressing rlk2
The present invention relates to a method of increasing resistance against fungal pathogens of the order pucciniales, preferably the family phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an rlk2 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells.
Basf Plant Science Company Gmbh
Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
The invention is generally directed to modified filamentous fungal host cells comprising one or more nucleic acids encoding one or more polypeptides under the control of one or more promoters that are functional in said cells. Methods of using the modified cells to express one or more polypeptides are also disclosed, including methods of screening cells transformed with one or more expression vectors comprising nucleic acids derived from synthetic or genomic nucleic acids including, cdnas.
Dyadic International, Inc.
Mycobacterium comprising expression vector with two auxotrophic selection markers and its use as vaccine
The invention relates to polynucleotides and recombinant cell strains comprising the polynucleotides and the uses thereof for the delivery of the polypeptides encoded by the polynucleotides to a subject in need thereof. In particular, the invention refers to polynucleotides comprising a polypeptide of interest, auxotrophy-complementing genes and the use thereof in a mycobacterial double auxotrophic host cell to achieve the stable expression of the polypeptide of interest by using an antibiotic-free plasmid selection system..
FundaciÓ Privada Institut De Recerca De La Sida - Caixa
Novel enzymes, enzyme components and uses thereof
The invention provides nucleic acid molecules which encodes a novel fatty acid desaturase, kcs, kcr and/or lacs from thraustochytrium aureum and sphaeroforma arctica. The invention also provides recombinant expression vectors containing said nucleic acid molecules, host cells into which the expression vectors have been introduced, and methods for large-scale production of long chain polyunsaturated fatty acids (lcpufas), e.g., ara, epa and dha and for screening for delta-4 desaturases..
Basf (china) Company Limited
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
The invention provides isolated anti-lp-pla2 antibodies that bind to lp-pla2. The invention also encompasses compositions comprising an anti-lp-pla2 antibody.
Scytodes venom fiber peptides, nucleic acids and methods of making and using
The present invention is directed to spider silk-like fibers, peptides comprising the fibers, nucleic acids encoding the peptides, nucleic acid constructs and recombinant expression vectors, fusion peptides and methods of making and using the foregoing.. .
Immune system mediator
The present invention discloses an isolated nucleic acid molecule encoding an israa polypeptide comprising a nucleotide sequence exhibiting at least 70% homology to the sequence represented by the nucleotide sequence seq id no: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule..
Arabian Gulf University
Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of vegf and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
Anges Mg, Inc.
Mammalian expression vector puhab
The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (mcs), designated puhab. The puhab vector comprises a high copy replication origin (cole1), a drug resistance gene (tk-hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hcmv/intron).
Merck Sharp & Dohme Corp.
Acid stable prolyl endopeptidases for degrading gluten
Gluten-degrading proteases can be used to degrade gluten and for making gluten-containing food safer for patients suffering from gluten intolerance. The present invention provides recombinant expression vectors encoding the proteases of the invention and methods for using such vectors to produce the encoded proteases.
Alvine Pharmaceuticals, Inc.
Compositions for the prevention and treatment of neuroinjury and methods of use thereof
A method for preventing or ameliorating secondary neuronal injury and inflammation following traumatic brain injury (tbi) is disclosed. The method comprises the step of administering into a subject in need of such treatment an effective amount of a pharmaceutical composition containing a neuregulin (nrg), a variant of nrg, or an expression vector encoding a nrg or a variant of nrg..
Vaccine formulations comprising saponin-containing adjuvants
The present invention provides for a novel oil-in-water (o/w) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof..
Production of infectious influenza viruses
The invention relates to a method for producing influenza infectious viruses wherein cho cells are infected with a seed of infectious influenza virus which has been generated by transfecting cells with an appropriate set of expression vectors. The invention also relates to a recombination cassette, and to a vector comprising said recombination cassette, that may be used in methods for producing infectious viruses, and particularly in the method according to the invention..
Novel soil microorganism, novel oxidoreductase separated from the soil microorganism, gene encoding the oxidoreductase, and producing aglycones using the microorganism, the oxidoreductase and the gene
The present invention relates to the novel rhizobium sp. Gin611 kctc11708bp or to cell extracts thereof, to a novel oxidoreductase which exhibits a glycolytic activity, to a gene encoding the oxidoreductase, to a recombinant strain comprising recombinant vector proteins or to an expression vector encoding recombinant proteins, and to a method for the glycolysis of natural products using same as a biocatalyst.
Development of the soluble recombinant crm197 production by e. coli
A method for recombinant production of a crm197 protein includes culturing a recombinant escherichia coli cell to produce said crm197 protein, and isolating said crm197 protein. The recombinant escherichia coli cell includes an expression vector, which contains a nucleic acid molecule that encodes a fusion protein that includes an e.
Development Center For Biotechnology
Yield and stress tolerance in transgenic plants iv
Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention have been shown to confer at least one regulatory activity and confer increased yield, greater height, greater early season growth, greater canopy coverage, greater stem diameter, greater late season vigor, increased secondary rooting, more rapid germination, greater cold tolerance, greater tolerance to water deprivation, reduced stomatal conductance, altered c/n sensing, increased low nitrogen tolerance, increased low phosphorus tolerance, or increased tolerance to hyperosmotic stress as compared to the control plant as compared to a control plant..
Monsanto Technology Llc
Plants with enhanced size and growth rate
Polynucleotides and polypeptides incorporated into expression vectors have been introduced into plants and were ectopically expressed. The polypeptides of the invention regulate transcription in these plants and have been shown to confer at least one regulatory activity that results in increased size, biomass, growth rate, and/or yield as compared to a control plant..
Mendel Biotechnology, Inc.
Novel monoclonal antibody binding specifically to dll4 and use thereof
The present invention relates to a novel monoclonal antibody that binds specifically to delta-like ligand (dll4), and more particularly to a monoclonal antibody that binds specifically to human delta-like ligand 4 to effectively inhibit the interaction between delta-like ligand 4 and notch receptor, a polynucleotide encoding the monoclonal antibody, an expression vector comprising the polynucleotide, a transformant comprising the expression vector, a method for preparing the monoclonal antibody, a pharmaceutical composition for preventing or treating cancer comprising the monoclonal antibody, a composition for diagnosing cancer comprising the monoclonal antibody, a method for diagnosing cancer using the monoclonal antibody, and a pharmaceutical composition for preventing or treating autoimmune disease comprising the monoclonal antibody.. .
Hanwha Chemical Corporattion
Glycoproteins for pseudotyping lentivectors
The invention relates to compositions and methods based on the use of viral g proteins to pseudotype vectors. The viral g proteins can be expressed by expression vectors and can be used to pseudotype lentiviral vectors.
Peptide inhibitors as novel anti-hiv therapeutics
The present invention relates to synthetic peptide inhibitors (seq id no. 67-71) useful as anti-hiv therapeutics.
Council Of Scientific & Industrial Research
Method for producing beta-santalene
The present invention provides a method of producing β-santalene, said method comprising contacting at least one polypeptide with farnesyl pyrophosphate (fpp). In particular, said method may be carried out in vitro or in vivo to produce β-santalene, a very useful compound in the fields of perfumery and flavoring.
Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases
The present invention relates to non-mammalian β-1,4-galactosyltransferases that can be used in their wild-type or in modified forms. The invention further relates to transformed plants and plant cells expressing non-mammalian β-1,4-galactosyltransferases and methods to produce glycoproteins with altered and preferably mammalian-type glycosylation.
Stichting Dienst Landbouwkundig Onderzoek
Lh-type bispecific antibody
Provided are a novel diabody type bispecific antibody, the function of which as a bispecific antibody is improved to provide a higher additional value, such as cost saving caused by a reduction in dose, to a drug; and a method for producing the same. A humanized diabody type bispecific antibody (lh-diabody type bispecific antibody) characterized in that an l-chain is located in the n-terminal side in each polypeptide (lh type); a humanized high-functional bispecific antibody which contains said lh diabody type bispecific antibody; a nucleic acid molecule encoding both of two kinds of single-stranded polypeptides constituting said bispecific antibody; and a method for producing said antibody which comprises culturing a host cell having been transformed by an expression vector containing said nucleic acid molecule..
Ovr110 antibody compositions and methods of use
Isolated antibodies and antigen binding fragments thereof directed against ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an ovr110-expressing cancer cells and alleviating or treating an ovr110-expressing cancer in a mammal.
Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
Disclosed herein are glycan-modified anti-cd4 monoclonal antibodies with n-linked glycans attached to the variable region. Expression vectors and cell lines useful for the production of such antibodies, and use of such antibodies for hiv prevention and therapy are also disclosed..
The invention relates to an anti-hsv antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of hsv-associated diseases in a subject; as defined in the claims.. .
Rheinische Friedrich-wilhelms-universität Bonn
Isolated polynucleotides comprising a gpr88 mini-promoters are provided. The mini-promoter may be operably linked to an expressible sequence, e.g.
The University Of British Columbia
Methods for treating cancer using anti-pd-1 antibodies
The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to pd-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided.
Ono Pharmaceutical Co., Ltd.
Alphao-superfamily conotoxin peptide, pharmaceutical composition and use thereof
The present invention pertains to fields of biochemistry and molecular biology, relates to an αo-superfamily conotoxin peptide, pharmaceutical composition thereof, preparation method and use thereof. The present invention further relates to a propeptide of the conotoxin peptide, nucleic acid construct thereof, expression vector and transformed cell thereof, and fusion protein thereof.
Transposition-mediated identification of specific binding or functional proteins
The method disclosed herein describes a novel technology offering unparalleled efficiency, flexibility, utility and speed for the discovery and optimization of polypeptides having desired binding specificity and/or functionality, including antigen-binding molecules such as antibodies and fragments thereof, for desired functional and/or binding phenotypes. The novel method is based on transposable constructs and diverse dna libraries cloned into transposable vectors and their transfection into host cells by concomitant transient expression of a functional transposase enzyme.
Vectors, host cells, and methods of production and uses
Antibody expression vectors and plasmids can incorporate various antibody gene portions for transcription of the antibody dna and expression of the antibody in an appropriate host cell. The expression vectors and plasmids have restriction enzyme sites that facilitate ligation of antibody-encoding dna into the vectors.
Janssen Biotech, Inc.
Ethane-1,2-diol producing microorganism and a producing ethane-1,2-diol from d-xylose using the same
Disclosed herein is a microorganism capable of producing ethane-1,2-diol from d-xylose, and a method for producing ethane-1,2-diol using the same. More specifically, the present invention relates to an engineered escherichia coli (e.
Myongji University Industry And Academia Cooperation Foundation
Biomass production increasing gene and transgenic plant using same
The present disclosure relates to, inter alia, a gene for increasing biomass production isolated from arabidopsis thaliana, and a method for producing a transgenic plant by using the same. More specifically, the present disclosure provides, inter alia, a composition for increasing production of plant biomass, a recombinant expression vector and a transgenic plant, comprising a base sequence encoding for the amino acid sequence of sequence number 2.
Postech Academy-industry Foundation
Mutant alpha-synuclein, and methods using same
The present invention relates to a mutant human alpha-synuclein with increased toxicity compared to wild-type alpha-synuclein, or a homologue thereof, wherein the mutant alpha-synuclein or homologue thereof comprises at least one amino acid substitution selected from the group consisting of a substitution at the alanine at position 56 (a56), at the alanine at position 76 (a76), at the methionine at position 127 (m127) and/or at the valine at position 118 (v118), as defined in the claims. Further, the invention relates to a polynucleotide encoding the mutant alpha-synuclein or homologue thereof, or an expression vector comprising said polynucleotide, a cell comprising the polynucleotide or expression vector, as defined in the claims.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.